Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trehalose dioctanoate
- Development stage
- Unknown
- Lead developer
- Trio Medicines
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Trehalose dioctanoate (Tr8) is a synthesized trehalose fatty acyl amphiphile, created by esterifying the two primary hydroxyls of trehalose with fatty acids. It functions as a super gelator, forming stable oleogels at low concentrations (minimum gelation concentration ≤ 0.2 wt%). These oleogels exhibit hexagonal columnar molecular packing and fibrillar networks. Tr8 is explored for its potential as an oil structuring agent in wax-free cosmetic formulations, such as lip balms, offering an alternative to traditional beeswax and plant wax products.
Beyond the preview
Go deeper on Trehalose dioctanoate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trehalose dioctanoate.